Form D · Biotechnology
Crescendo Bioscience, Inc.
South San Francisco, CA · CIK 0001328976
Offering snapshot reported Jan 2, 2013 · SEC filing
- Reported sold
- $28.5M Offering amount: $28.5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 19, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 2, 2013 | Initial | $28,454,396 | No comparison | 9 | SEC filing |
| Sep 20, 2011 | Initial | $25,000,000 | No comparison | 1 | SEC filing |
| Jun 20, 2011 | Initial | $31,019,775 | No comparison | 10 | SEC filing |
| Jul 7, 2010 | Amendment | $37,600,003 | $10,000,002vs Dec 23, 2009 | 4 | SEC filing |
| Dec 23, 2009 | Amendment | $27,600,001 | $7,500,002vs Nov 20, 2009 | 4 | SEC filing |
| Nov 20, 2009 | Amendment | $20,099,999 | No comparison | 4 | SEC filing |
| Jun 25, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 6, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 30, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 27, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $1.18M
- Form D file number
- 021-189231
Total Offering and Sales Amounts assume the exercise of warrants ($454,396.01)
Sale and issuance of (i) Series D Preferred Stock, (ii) Warrants, (iii) Series D Preferred Stock underlying Warrants and (iv) Common Stock issuable upon conversion of Series D Preferred Stock.
The finders' fees contain $940,000 cash plus warrants
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| William J. Kridel | 704171 | FERGHANA SECURITIES, INC. · CRD 43430 |
| E. Hunterson Herie | 2431896 | FERGHANA SECURITIES, INC. · CRD 43430 |
| A. Rawle Michelson | 1507251 | FERGHANA SECURITIES, INC. · CRD 43430 |
Source: Form D, filed Jan 2, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brook Byers | Director |
| Leon Chen | Director |
| Michael Goldberg | Director |
| Josh Green | Director |
| William A. Hagstrom | Director, Executive |
| Timothy G. Henn | Executive |
| Gary Kurtzman | Director |
| Larry Leisure | Director |
| Jack Oliver | Director |
| Amy Paye | Executive |
| George Rehm | Director |
| William R. Salisbury | Executive |
| Sue Siegel | Director |
| Ralph Snyderman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
341 Oyster Point Blvd.
South San Francisco, CA, 94080
South San Francisco, CA, 94080